The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Oncology Treatment Drug Market Research Report 2025

Global Oncology Treatment Drug Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1721907

No of Pages : 106

Synopsis
Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

When these extra cells form a mass or a solid lump of tissue, it is called a tumor. Most cancers form tumors, but not all do. Tumors may be either benign or cancerous.

Benign tumors do not spread to other parts of the body and are rarely life-threatening. Many breast lumps, for example, are benign. Benign tumors are not cancer.

Malignant tumors crowd out healthy cells, interfere with body functions, and draw nutrients from body tissues. Malignant tumors can also spread to other parts of the body via the blood or lymphatic system, forming satellite tumors, called secondary cancers or metastases. Malignant tumors are cancer.
The global Oncology Treatment Drug market was valued at US$ 197440 million in 2023 and is anticipated to reach US$ 342140 million by 2030, witnessing a CAGR of 8.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Oncology Treatment Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Treatment Drug.
Report Scope
The Oncology Treatment Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oncology Treatment Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Treatment Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Astellas
Ipsen
Sanofi
Bayer
Biogen Idec
Teva
Otsuka
Eisai
Merck KGaA
Gilead Sciences
Segment by Type
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
Segment by Application
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oncology Treatment Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Treatment Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Oncology Treatment Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Treatment Drug Market Perspective (2019-2030)
2.2 Oncology Treatment Drug Growth Trends by Region
2.2.1 Global Oncology Treatment Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oncology Treatment Drug Historic Market Size by Region (2019-2024)
2.2.3 Oncology Treatment Drug Forecasted Market Size by Region (2025-2030)
2.3 Oncology Treatment Drug Market Dynamics
2.3.1 Oncology Treatment Drug Industry Trends
2.3.2 Oncology Treatment Drug Market Drivers
2.3.3 Oncology Treatment Drug Market Challenges
2.3.4 Oncology Treatment Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oncology Treatment Drug Players by Revenue
3.1.1 Global Top Oncology Treatment Drug Players by Revenue (2019-2024)
3.1.2 Global Oncology Treatment Drug Revenue Market Share by Players (2019-2024)
3.2 Global Oncology Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oncology Treatment Drug Revenue
3.4 Global Oncology Treatment Drug Market Concentration Ratio
3.4.1 Global Oncology Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Treatment Drug Revenue in 2023
3.5 Oncology Treatment Drug Key Players Head office and Area Served
3.6 Key Players Oncology Treatment Drug Product Solution and Service
3.7 Date of Enter into Oncology Treatment Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Treatment Drug Breakdown Data by Type
4.1 Global Oncology Treatment Drug Historic Market Size by Type (2019-2024)
4.2 Global Oncology Treatment Drug Forecasted Market Size by Type (2025-2030)
5 Oncology Treatment Drug Breakdown Data by Application
5.1 Global Oncology Treatment Drug Historic Market Size by Application (2019-2024)
5.2 Global Oncology Treatment Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oncology Treatment Drug Market Size (2019-2030)
6.2 North America Oncology Treatment Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oncology Treatment Drug Market Size by Country (2019-2024)
6.4 North America Oncology Treatment Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oncology Treatment Drug Market Size (2019-2030)
7.2 Europe Oncology Treatment Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oncology Treatment Drug Market Size by Country (2019-2024)
7.4 Europe Oncology Treatment Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oncology Treatment Drug Market Size (2019-2030)
8.2 Asia-Pacific Oncology Treatment Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oncology Treatment Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Oncology Treatment Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oncology Treatment Drug Market Size (2019-2030)
9.2 Latin America Oncology Treatment Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oncology Treatment Drug Market Size by Country (2019-2024)
9.4 Latin America Oncology Treatment Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oncology Treatment Drug Market Size (2019-2030)
10.2 Middle East & Africa Oncology Treatment Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oncology Treatment Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Oncology Treatment Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Oncology Treatment Drug Introduction
11.1.4 Roche Revenue in Oncology Treatment Drug Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Detail
11.2.2 Celgene Business Overview
11.2.3 Celgene Oncology Treatment Drug Introduction
11.2.4 Celgene Revenue in Oncology Treatment Drug Business (2019-2024)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Oncology Treatment Drug Introduction
11.3.4 Novartis Revenue in Oncology Treatment Drug Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Oncology Treatment Drug Introduction
11.4.4 Bristol-Myers Squibb Revenue in Oncology Treatment Drug Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Oncology Treatment Drug Introduction
11.5.4 Johnson & Johnson Revenue in Oncology Treatment Drug Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Detail
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Oncology Treatment Drug Introduction
11.6.4 Merck & Co. Revenue in Oncology Treatment Drug Business (2019-2024)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Oncology Treatment Drug Introduction
11.7.4 AstraZeneca Revenue in Oncology Treatment Drug Business (2019-2024)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Oncology Treatment Drug Introduction
11.8.4 Pfizer Revenue in Oncology Treatment Drug Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Oncology Treatment Drug Introduction
11.9.4 Amgen Revenue in Oncology Treatment Drug Business (2019-2024)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Oncology Treatment Drug Introduction
11.10.4 Eli Lilly Revenue in Oncology Treatment Drug Business (2019-2024)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Oncology Treatment Drug Introduction
11.11.4 AbbVie Revenue in Oncology Treatment Drug Business (2019-2024)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Detail
11.12.2 Takeda Business Overview
11.12.3 Takeda Oncology Treatment Drug Introduction
11.12.4 Takeda Revenue in Oncology Treatment Drug Business (2019-2024)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Detail
11.13.2 Astellas Business Overview
11.13.3 Astellas Oncology Treatment Drug Introduction
11.13.4 Astellas Revenue in Oncology Treatment Drug Business (2019-2024)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Detail
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Oncology Treatment Drug Introduction
11.14.4 Ipsen Revenue in Oncology Treatment Drug Business (2019-2024)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Oncology Treatment Drug Introduction
11.15.4 Sanofi Revenue in Oncology Treatment Drug Business (2019-2024)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Detail
11.16.2 Bayer Business Overview
11.16.3 Bayer Oncology Treatment Drug Introduction
11.16.4 Bayer Revenue in Oncology Treatment Drug Business (2019-2024)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Detail
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Oncology Treatment Drug Introduction
11.17.4 Biogen Idec Revenue in Oncology Treatment Drug Business (2019-2024)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Detail
11.18.2 Teva Business Overview
11.18.3 Teva Oncology Treatment Drug Introduction
11.18.4 Teva Revenue in Oncology Treatment Drug Business (2019-2024)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Detail
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Oncology Treatment Drug Introduction
11.19.4 Otsuka Revenue in Oncology Treatment Drug Business (2019-2024)
11.19.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Detail
11.20.2 Eisai Business Overview
11.20.3 Eisai Oncology Treatment Drug Introduction
11.20.4 Eisai Revenue in Oncology Treatment Drug Business (2019-2024)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Detail
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Oncology Treatment Drug Introduction
11.21.4 Merck KGaA Revenue in Oncology Treatment Drug Business (2019-2024)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Detail
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Oncology Treatment Drug Introduction
11.22.4 Gilead Sciences Revenue in Oncology Treatment Drug Business (2019-2024)
11.22.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’